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Abstract
Background: Increased resting heart rate (RHR) may be associated with increased cardiovascular
morbidity. Our aim was to explore the possibility that increased RHR is associated with the
prevalence of the metabolic syndrome (MetS) in a sample of apparently healthy individuals and
those with cardiovascular risk factors.
Methods: We performed a cross-sectional analysis in a large sample of apparently healthy
individuals who attended a general health screening program and agreed to participate in our
survey. We analyzed a sample of 7706 individuals (5106 men and 2600 women) with 13.2% of men
and 8.9% of the women fulfilling the criteria for the MetS. The participants were divided into
quintiles of resting heart rate. Multiple adjusted odds ratio was calculated for having the MetS in
each quintile compared to the first.
Results: The multi-adjusted odds for the presence of the MetS increased gradually from an
arbitrarily defined figure of 1.0 in the lowest RHR quintile (<60 beats per minute (BPM) in men and
<64 BPM in women) to 4.1 and 4.2 in men and women respectively in the highest one (≥80 BPM
in men and ≥82 BPM in women).
Conclusion: Raised resting heart rate is significantly associated with the presence of MetS in a
group of apparently healthy individuals and those with an atherothrombotic risk. The strength of
this association supports the potential presence of one or more shared pathophysiological
mechanisms for both RHR and the MetS.
Background
There are multiple lines of emerging evidence which sug-
gest that resting heart rate (RHR) is associated with the
presence and/or the potential to develop cardiovascular
disease [1-4]. We have currently analyzed the association
between RHR and the presence of the metabolic syn-
drome (MetS), a recognized risk factor for cardiovascular
disease [5,6]. A significant association might explain, at
least in part, the observed link between RHR and cardio-
vascular disease. It can also raise the possibility of the
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We have currently analyzed data which has been collected
during the last five years from the Tel Aviv Medical Center
Inflammation Survey (TAMCIS), a registered data bank of
the Israeli Ministry of Justice [7-13]. This is a relatively
large cohort of individuals who attended our medical cen-
tre for a routine annual check-up and gave their written
informed consent for participation according to the
instructions of the local ethics committee. A total of
14,888 subjects agreed to participate (9,412 males, 5,476
females). Multiple exclusions were conducted in order to
analyze subjects without conditions that might influence
heart rate or MetS parameters. Firstly, 2,657 subjects were
excluded for having a current or past medical history of
malignancy or immunosuppressive therapy, known
inflammatory disease, pregnancy, steroidal or non-steroi-
dal anti-inflammatory treatment, acute infection or hav-
ing undergone any invasive procedures (surgery,
catheterization, etc) during the prior 6 months. We fur-
ther excluded 463 individuals with at least one proven
past atherothrombotic event (myocardial infarction, cere-
brovascular event or peripheral arterial disease) and 348
individuals due to absent recorded resting heart rate or
any of the measurements of parameters relevant to the
metabolic syndrome. In order to minimise the possible
influence of medications on heart rate, we further
excluded 930 individuals who were taking nitrates, alpha
blockers, beta blockers, calcium channel blockers,
antiarrhythmic drugs, thyroid replacement medications
or digoxin. We excluded a further 1,131 individuals with
anemia, defined as having an hemoglobin concentration
below the lower normal limit according to our laboratory
(135 g/l and 117 g/l for men and women respectively)
and 1,653 currently smoking individuals.
Determination of RHR
Baseline RHR was obtained manually at enrolment with
one radial pulse measurement over a period of 60 seconds
with the patient in a sitting position, after sitting in a quiet
room for 5 minutes.
Definition of MetS
The diagnosis of the metabolic syndrome was based on
the National Cholesterol Education Program (NCEP) ATP
III Criteria [14] with the modified Impaired Fasting Glu-
cose criteria of the American Diabetes Association (ADA)
[15] as proposed by the updated American Heart Associa-
tion (AHA)/National Heart, Lung, and Blood Institute
(NHLBI) scientific statement [16]. Accordingly, the crite-
ria for MetS were based upon the existence of three or
more of the following: (1) waist circumference > 88 cm in
women or >102 cm in men; (2) a fasting triglyceride con-
centration >1.7 mmol/l; (3) an high density lipoprotein
cholesterol (HDL-C) concentration <1.3 mmol/l in
women or <1.0 mmol/l in men (4) a blood pressure
above 130 mm Hg (systolic) or 85 mm Hg (diastolic) or
use of antihypertensive drugs; and (5) a fasting plasma
glucose >5.55 mmol/l or use of antidiabetic drugs.
Laboratory methods
Blood was drawn during the morning hours following a
fasting period of at least 12 hours using a standard Vacu-
tainer gel tube (Becton Dickinson and company, New Jer-
sey, USA). Triglycerides, HDL-C and glucose
concentration were measured using a Bayer Advia 1650
chemistry analyzer and respective Bayer kits (Bayer
healthcare diagnostics division, Newbury, UK). Blood
pressure was obtained on two separate measurements fol-
lowing a five minute resting period.
Statistical analysis
All data was summarized and displayed as mean (Stand-
ard deviation (SD)) for the continuous variables and as
the number of patients (percentage) in each group for cat-
egorical variables.
In order to characterize the population we divided the
patients of each gender into quintiles of resting heart rate
and analyzed all results accordingly. For all categorical
variables the Chi-Square test was used for assessing the
overall statistical significance between the quintiles, while
the One-Way Analysis of Variance was used for all contin-
uous variables as well as for calculating the P value for the
linear trend between the quintiles.
In order to better evaluate the magnitude of the associa-
tion between each component of the MetS and the RHR,
we calculated the estimated marginal means for the
groups with and without each component, adjusting for
age, former or never smoking status, alcohol consump-
tion, exercise activity, oral temperature, family history of
premature cardiovascular disease (CVD), use of aspirin as
well as the presence of all four others components of the
MetS, using analysis of covariance (ANCOVA) under a
general linear model.
Finally, in order to quantify the relative odds of having the
MetS as a function of the quintiles of RHR, we arbitrarily
defined the lowest quintile as 1.0 and calculated the
adjusted odds ratio (OR) for having the MetS for each of
the higher quintiles with adjustment for age, former or
never smoking status, alcohol consumption, exercise
activity, oral temperature, family history of CVD and the
use of aspirin, using logistic regression. All above analyses
were considered significant at p < 0.05 (two tailed). ThePage 2 of 6
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evaluation (SSPS Inc., Chicago, IL, USA).
Results
We have currently performed a cross-sectional analysis
regarding the presence or absence of the MetS in a sample
of 5,106 men and 2,600 women with respective mean
(SD) ages of 43 (11) and 44 (11) years. This cohort
included a total of 674 males and 231 females defined as
having the MetS. The baseline characteristics of both men
and women in relation to quintiles of RHR are reported in
Tables 1 and 2, respectively. It can be seen that the preva-
lence of the MetS increases with the elevation of RHR in
both men and women. In fact, the prevalence of MetS was
found to be 6.2% and 5.2% (for men and women, respec-
tively) in the first quintile of RHR and this increased up
gradually to the respective percentages of 21.1% and
13.3% in the fifth quintile (Figure 1). With the exception
of HDL cholesterol, a significant association was noted
between RHR and each of the components of the MetS for
both genders (Table 3). Finally, we have calculated the
crude and multi-adjusted odds for the presence of MetS in
both genders according to quintiles of the RHR (Table 4
and Figure 2). Again, a clear and sequential increment is
seen for the odds of having MetS according to the quin-
tiles of the RHR in both genders.
Discussion
We have presently documented a relatively strong associ-
ation between RHR and the presence of the MetS. Such a
strong association might suggest that there is a shared
pathophysiological pathway which is yet to be revealed.
We believe therefore, that RHR is an extremely easy-to-
perform and almost costless parameter which may
improve the early detection of cardiovascular risk. Of spe-
cial note might be the fact that even a small increment in
RHR (for example from the first to the second quintile)
had a clear influence on the odds of having MetS. Moreo-
ver, the prevalence of the MetS was three times higher in
individuals in the fourth quintile and this was still within
the "normal" RHR that is - to date - accepted as being
between 60 and 80. Again, this might be another observa-
tion to support the notion that one should look at RHR as
a continuous variable, putting into perspective the cur-
rently used normal limits.
Sympathetic overactivity or parasympathetic underactiv-
ity might underly the aforementioned observation. In fact,
sympathetic imbalance has been described for several of
the components of the MetS including hypertension [17],
waist circumference [18-21], impaired fasting glucose
[22,23] as well as hypertriglyceridemia [24]. Deniz et al
[25], demonstrated a significant difference in RHR
between MetS and controls (105 vs. 88, P < 0.001). That
however, was a small case-control study involving 64
young male subjects with MetS and 40 overweight
matched control subjects without MetS. In addition,
Deniz et al found a significant association between the
presence of the MetS and impaired heart rate recovery and
low exercise capacity [25]. Thus, one could argue that our
Table 1: Characteristics* of men according to quintiles of resting heart rate
Men (N = 5,106) 1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile ANOVA P for linear trend
HR < 60 60 ≤ HR < 67 67 ≤ HR < 73 73 ≤ HR < 80 HR ≥ 80 P Value
n = 947 n = 1137 n = 1020 n = 1009 n = 993
Age (years) 43 (11) 44 (11) 44 (11) 43 (11) 42 (10) 0.080 0.135
Waist (cm) 92 (9) 94 (9) 95 (11) 96 (10) 96 (11) < 0.001 < 0.001
BMI (kg/m2) 25.8 (3.0) 26.4 (3.2) 26.8 (3.7) 27.0 (3.8) 27.3 (4.1) < 0.001 < 0.001
Diastolic BP (mmHg) 76 (7) 77 (7) 78 (8) 78 (8) 80 (9) < 0.001 < 0.001
Systolic BP (mmHg) 121 (12) 123 (14) 123 (14) 123 (14) 127 (15) < 0.001 < 0.001
Alcohol consumption 
(glasses/week)
1.4 (2.2) 1.4 (2.5) 1.1 (1.7) 1.2 (2.4) 0.8 (1.6) < 0.001 < 0.001
Physical exercise (hours/week) 3.3 (3.1) 2.4 (2.6) 2.3 (2.7) 2.0 (2.5) 1.8 (2.4) < 0.001 < 0.001
Smoking status, n(%)
Former 305 (32.2) 347 (30.5) 309 (30.3) 271 (26.9) 268 (27.0) 0.031
Never 642 (67.8) 790 (69.5) 711 (69.7) 738 (73.1) 725 (73.0)
Hypertension, n (%) 123 (13.0) 196 (17.2) 200 (19.6) 203 (20.1) 287 (28.9) < 0.001
Metabolic Syndrome, n (%) 59 (6.2) 121 (10.6) 127 (12.5) 157 (15.6) 210 (21.1) < 0.001
Glucose (mmol/l) 5.08 (0.64) 5.15 (0.69) 5.19 (0.79) 5.26 (0.96) 5.46 (1.31) < 0.001 < 0.001
HDL Cholesterol (mmol/l) 1.36 (0.29) 1.31 (0.26) 1.31 (0.26) 1.29 (0.26) 1.28 (0.23) < 0.001 < 0.001
LDL Cholesterol (mmol/l) 3.09 (0.78) 3.18 (0.80) 3.19 (0.82) 3.19 (0.84) 3.22 (0.83) 0.009 0.001
Triglycerides (mmol/l) 1.08 1.21 1.25 1.34 1.38 < 0.001 < 0.001
* data presented as arithmetic mean (standard deviation) for continuous variables (with the exception of triglycerides which are presented as 
geometric mean) and number of individuals (percentage) for dichotomous variables.
** list of abbreviations: HR = heart rate; ANOVA = analysis of variance; BMI = body mass index; BP = blood pressure; HDL = high-density 
lipoprotein; LDL = low density lipoprotein.Page 3 of 6
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the association was not known. Our study is significant,
therefore, in the determination of the strength of the asso-
ciation, a strength that could support shared pathophysi-
ological mechanisms. These suggested mechanisms might
work in both directions since the treatment of the dysme-
tabolism might have a favorable effect on the heart rate
[26].
In a previous study which solely involved men, we
addressed the question of the association between RHR
and the presence of microinflammatory changes [10]. It is
known that individuals with the MetS do harbor a low
grade inflammation but the presence of MetS in relation
to RHR was not explored in that study.
Resting heart rate measurements are known to be influ-
enced by multiple factors. In the current study design,
although there were multiple exclusions and statistical
adjustments performed, we could not account for every
factor. Thus we acknowledge several limitations to the
present study. Firstly, the RHR was obtained by single
Table 2: Characteristics* of women according to quintiles of resting heart rate
Women (n = 2,600) 1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile ANOVA P for linear trend
HR < 64 64 ≤ HR < 70 70 ≤ HR < 76 76 ≤ HR < 82 HR ≥ 82 P Value
n = 518 n = 519 n = 571 n = 454 n = 538
Age (years) 47 (10) 46 (10) 44 (10) 42 (10) 41 (11) < 0.001 < 0.001
Waist (cm) 80 (11) 81 (11) 81 (11) 83 (13) 82 (13) 0.006 < 0.001
BMI (kg/m2) 24.5 (3.9) 24.8 (4.1) 25.0 (4.2) 25.6 (5.3) 25.3 (5.1) 0.002 < 0.001
Diastolic BP (mmHg) 73 (7) 73 (8) 73 (8) 74 (8) 75 (9) < 0.001 < 0.001
Systolic BP (mmHg) 115 (14) 116 (15) 115 (15) 116 (15) 118 (16) 0.003 0.001
Alcohol consumption 
(glass/week)
0.7 (1.6) 0.5 (1.3) 0.6 (1.3) 0.5 (1.2) 0.4 (1.0) 0.007 0.006
Physical exercise (hours/week) 2.7 (2.8) 2.0 (2.4) 1.7 (2.4) 1.7 (2.5) 1.6 (2.6) < 0.001 < 0.001
Smoking status, n(%)
Former 158 (30.5) 128 (24.7) 140 (24.5) 101 (22.2) 105 (19.5) 0.001
Never 360 (69.5) 391 (75.3) 431 (75.5) 353 (77.8) 433 (80.5)
Hypertension, n (%) 45 (8.7) 56 (10.8) 50 (8.8) 55 (12.1) 81 (15.1) 0.004
Metabolic Syndrome, n (%) 27 (5.2) 36 (6.9) 47 (8.2) 47 (10.4) 74 (13.3) < 0.001
Glucose (mmol/l) 4.89 (0.52) 4.90 (0.51) 5.00 (0.68) 5.01 (0.87) 5.14 (0.91) < 0.001 < 0.001
HDL Cholesterol (mmol/l) 1.72 (0.39) 1.70 (0.37) 1.68 (0.37) 1.66 (0.37) 1.68 (0.40) 0.165 0.031
LDL Cholesterol (mmol/l) 3.07 (0.83) 3.09 (0.86) 3.06 (0.87) 3.03 (0.82) 3.02 (0.82) 0.635 0.165
Triglycerides (mmol/l) 0.89 0.96 1.03 1.04 1.11 < 0.001 < 0.001
* data presented as arithmetic mean (standard deviation) for continuous variables (with the exception of triglycerides which are presented as 
geometric mean) and number of individuals (percentage) for dichotomous variables.
** list of abbreviations: HR = heart rate; ANOVA = analysis of variance; BMI = body mass index; BP = blood pressure; HDL = high-density 
lipoprotein; LDL = low density lipoprotein.
Table 3: Estimated marginal mean* (95% confidence interval) of resting heart rate in relation to each component of the MetS
Men Component absent Component present P Value
Hypertension 71.1 (70.0-72.2) 74.5 (73.4-75.6) < 0.001
Waist circumference 71.5 (70.5-72.5) 74.1 (72.9-75.3) < 0.001
IFG 71.0 (69.9-72.0) 74.7 (73.5-75.8) < 0.001
Triglycerides 71.9 (70.8-72.9) 73.8 (72.6-74.9) < 0.001
HDL Cholesterol 72.8 (71.8-73.8) 72.8 (71.5-74.1) 0.966
Women
Hypertension 74.6 (72.6-76.5) 77.8 (75.8-79.8) < 0.001
Waist circumference 75.5 (73.5-77.4) 76.9 (75.0-78.9) 0.011
IFG 74.9 (73.0-76.8) 77.5 (75.4-79.6) < 0.001
Triglycerides 75.0 (73.1-76.9) 77.4 (75.3-79.5) < 0.001
HDL Cholesterol 76.0 (74.1-77.9) 76.4 (74.3-78.5) 0.524
*All means are adjusted for age, former or never smoking status, family history of CVD, aspirin usage, alcohol consumption, measured oral 
temperature and physical exercise, and in addition, to the presence of all other components of the MetS.
** list of abbreviations: MetS = metabolic syndrome; IFG = impaired fasting glucose; HDL = high-density lipoprotein.Page 4 of 6
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repeated measurements. Since all of the analyses were
based on this single measurement and since uncondi-
tioned individuals might require more time to return to
their usual heart rate at rest, it is possible that our results
were accordingly influenced. On the other hand, we
believe that the large number of individuals analysed
dilutes this possible effect and makes it unlikely that
repeated measurements or longer resting prior to meas-
urement would influence our results significantly. Sec-
ondly, we did not exclude patients with abnormal thyroid
function, mainly because the survey does not include
those measurements. We did however, exclude all individ-
uals reporting thyroid disease or taking thyroid replace-
ment therapy. Thirdly, we did not measure insulin levels
and thus could not calculate the HOMA index. Lacking
this objective laboratory parameter, we could only assume
that there is a shared pathophysiological pathway and
that future studies in this field might reveal what it is.
Fourthly, the individuals were not evaluated routinely by
echocardiography and thus we were not able to exclude
individuals with a cardiomyopathy, including such a car-
diomyopathy secondary to tachycardia. Due to the rela-
tively healthy population evaluated and the large number
of individuals we believe that the number of individuals
with a significant cardiomyopathy included is negligible
and would therefore not have influenced the results sig-
nificantly. Finally, we did not exclude patients regularly
performing sport activity, although we did adjust our
results to their levels of physical activity. In addition, since
our population is mainly referred from places of employ-
ment, there exists the possibility of "healthy worker"
Table 4: OR (95% CI) for having the MetS according to quintiles of resting heart rate
1st Quintile 2nd Quintile 3rd Quintile 4th Quintile 5th Quintile
Men HR < 60 60 ≤ HR < 67 67 ≤ HR < 73 73 ≤ HR < 80 HR ≥ 80
n = 947 n = 1137 n = 1020 n = 1009 n = 993
Crude OR 1.00 1.8 (1.3-2.5)§ 2.1 (1.6-3.0)§ 2.8 (2.0-3.8)§ 4.0 (3.0-5.5)§
Multiadjusted* OR 1.00 1.9 (1.3-2.7)§ 2.1 (1.4-2.9)§ 2.8 (2.0-4.0)§ 4.2 (3.0-5.9)§
Women HR < 64 64 ≤ HR < 70 70 ≤ HR < 76 76 ≤ HR < 82 HR ≥ 82
n = 518 n = 519 n = 571 n = 454 n = 538
Crude OR 1.00 1.4 (0.8-2.3) 1.6 (1.0-2.7) 2.1 (1.3-3.4)§ 2.9 (1.8-4.6)§
Multiadjusted* OR 1.00 1.2 (0.7-2.2) 1.9 (1.1-3.3)† 2.9 (1.7-4.9)§ 3.6 (2.2-6.1)§
† - 0.05 > P ≥ 0.01; § - P < 0.01
* Adjusted for age, former or never smoking status, family history of CVD, aspirin usage, alcohol consumption, measured oral temperature and 
physical exercise.
** list of abbreviations: MetS = metabolic syndrome; OR = odds ratio; CI = confidence interval; HR = heart rate.
Percentage of individuals fulfilling the criteria for the meta-boli  syndrome in each quinti e of r sting heart ratFigure 1
Percentage of individuals fulfilling the criteria for the 
metabolic syndrome in each quintile of resting heart 
rate.
Multi-Adjusted OR for having the Metabolic SyndromeFigure 2
Multi-Adjusted Odds Ratio (95% Confidence Interval) 
for having the Metabolic Syndrome.Page 5 of 6
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selection bias and thus generalization of the results might
be limited.
The question of "normalcy" for RHR remains. Our study
does support, at least in relation to the presence of the
MetS, the finding that the lower the RHR is, the lower the
dysmetabolic risk. This information might be relevant if
new "normal values" for RHR are to be determined in the
future.
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